The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Evaluating neoadjuvant FLOT response and the need for biomarker-guided strategies in GEA
Radka Obermannova, MD, PhD, Masaryk University, Brno, Czech Republic, emphasizes that the findings from a real-world study (ACTRN12622000180718) in gastroesophageal adenocarcinoma (GEA) are not practice-changing due to limitations such as non-unified tumor regression grade (TRG) evaluation and differences in baseline characteristics. Despite its ambition, some valuable treatment benefits may have been missed. For patients not responding to neoadjuvant FLOT, more biomarker-driven strategies are needed. Biomarker-guided algorithms, like PET scans, may help predict non-responders and guide treatment adjustments before surgery, especially as targeted therapies and immunotherapies in adjuvant settings have faced challenges. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
